RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Keyphrases

• Predictive Biomarker 100%
• Pathway mutation 100%
• Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia 100%
• RAS Pathway 100%
• Treatment Adaptation 100%
• Subclonal mutations 66%
• MEK Inhibitor (MEKi) 33%
• Prednisolone 33%
• Trametinib 33%
• ETV6-RUNX1 16%
• TCF3-PBX1 16%
• Standard Risk 16%
• Mutation Frequency 16%
• High Risk 16%
• Initial Diagnosis 16%
• Pathway Genes 16%
• Prognostic Value 16%
• RAS mutant 16%
• Highly Sensitive 16%
• Mutant Cells 16%
• Resistant Cells 16%
• Bother 16%
• BCR-ABL1-like 16%
• BCR-ABL1 16%
• Inhibitor Treatment 16%
• Well-defined 16%
• Hyperdiploid 16%
• Chemotherapy Resistance 16%
• Unfavorable Outcome 16%
• Newly Diagnosed 16%
• Unfavorable Risk 16%
• Risk Parameters 16%
• Quantitative Methods 16%
• Targeted Deep Sequencing 16%
• Frequency Values 16%

Biochemistry, Genetics and Molecular Biology

• Trametinib 50%